UK markets close in 4 hours 6 minutes

Aurora Cannabis Inc. (ACB.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
1.7000-0.0600 (-3.41%)
At close: 04:00PM EDT
Full screen
Previous close1.7600
Open1.7000
Bid1.7000 x 0
Ask1.7100 x 0
Day's range1.6300 - 1.7400
52-week range1.5600 - 11.1200
Volume1,693,759
Avg. volume2,386,524
Market cap506.17M
Beta (5Y monthly)3.13
PE ratio (TTM)N/A
EPS (TTM)-6.1050
Earnings date26 Sept 2022 - 30 Sept 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.61
  • Motley Fool

    Is Aurora Cannabis Too Cheap to Pass Up Right Now?

    Aurora Cannabis (NASDAQ: ACB) is one of the most beaten-down cannabis stocks in the entire industry. Investors will recall that back in 2018, Aurora announced it was acquiring medical marijuana company MedReleaf for more than $2.5 billion in what at the time was the sector's largest deal. Today, Aurora is worth about one-fifth of that value, with a market cap of over $400 million.

  • Motley Fool

    Can These Beaten-Down Growth Stocks Be Revived?

    The global legal marijuana market could grow at a compound rate of 25% by 2030, according to Grand View Research. One-time investor favorites Canopy Growth (NASDAQ: CGC) and Aurora Cannabis (NASDAQ: ACB) have seen their stocks dip more than 90% in the last three years. Aurora and Canopy have been in pursuit of positive earnings before interest, taxes, depreciation, and amortization (EBITDA) for quite a while now, but have failed to reach their goal.

  • Motley Fool

    2 Reasons Aurora Could Recover From Significant Pruning

    Aurora Cannabis (NASDAQ: ACB) announced in early June an additional round of cost-saving measures as part of its business transformation plan that has already brought on major adjustments to the company in the past two years. Aurora's shares dropped throughout June after it bought back millions of dollars in convertible debt, announced it would close a major facility, and laid off a huge chunk of its workforce. All this is bad news for the international cannabis operator -- but a strong showing in Europe's medical cannabis market, and its major presence in Canadian medical cannabis, should provide long-term hope amid the short-term gloom.